Pharmacoeconomic aspects of COVID-19 treatment
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.086
Abstract
The article provides an overview of global trends in various treatment approaches for COVID-19 in terms of pharmacoeconomic effectiveness. Different strategies for managing patients with the new coronavirus infection, separate groups of drugs are considered. The current clinical trials for COVID-19, the main directions, problems and challenges facing the healthcare system are discussed in detail. The aspects of the economic efficiency of various measures to prevent the spread of COVID-19 are presented. A thorough study of the pharmacoeconomic features of the new coronavirus infection will allow to develop effective standards for planning the process of supply for medical organizations in the pandemic.
About the Authors
I. V. Rogova
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Irina V. Rogova – Head of Department
RSCI SPIN-code: 3403-1923
20/1 Delegatskaya Str., Moscow 127473, Russia
E. A. Zhidkova
Yevdokimov Moscow State University of Medicine and Dentistry; Central Directorate of Healthcare – branch of Russian Railways JSC
Russian Federation
Russian Federation
Elena A. Zhidkova – MD, PhD, Tutor; Head
20/1 Delegatskaya Str., Moscow 127473, Russia
52а Malaya Gruzinskaya Str., Moscow 123557, Russia
I. A. Popova
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Inga A. Popova – MD, PhD, Doctoral Student
RSCI SPIN-code: 7619-7822
20/1 Delegatskaya Str., Moscow 127473, Russia
A. V. Zaborovskiy
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Andrey V. Zaborovskiy – Dr. Med. Sc., Associate Professor, Chief of Chair
WoS ResearcherID: Y-3653-2018; RSCI SPIN-code: 9592-2405
20/1 Delegatskaya Str., Moscow 127473, Russia
K. G. Gurevich
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Konstantin G. Gurevich – Dr. Med. Sc., Professor, Chief of Chair
WoS ResearcherID: C-2071-2017; Scopus Author ID: 55197151600; RSCI SPIN-code: 4344-3045
20/1 Delegatskaya Str., Moscow 127473, Russia
References
1. Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20 (5): 533–4. https://doi.org/10.1016/S1473-3099(20)30120-1.
2. Leonardi Vinci D., Polidori C., Polidori P. The healthcare and pharmaceutical vulnerability emerging from the new coronavirus outbreak. Eur J Hosp Pharm. 2020; 27 (3): 129–30. https://doi.org/10.1136/ejhpharm-2020-00227.
3. Perkhov V.I., Pesennikova E.V. Variety of forms of reaction of health care systems of particular countries to the predicted COVID-19 pandemic. Medicine and Health Care Organization. 2020; 5 (3): 4–12 (in Russ.).
4. Pan W., Huang G., Shi Y., et al. COVID-19: short-term influence on China's economy considering different scenarios. Glob Chall. 2020; 5 (3): 2000090. https://doi.org/10.1002/gch2.202000090.
5. Sokolov E.V., Kostyrin E.V. Expenses and losses of the state and russian citizens to fight COVID-19 and the need to return to normal life. Economics and Management: Problems, Solutions. 2020; 1 (7): 65–76 (in Russ.).
6. Jin H., Wang H., Li X., et al. Economic burden of COVID-19, China, January-March, 2020: a cost-of-illness study. Bull World Health Organ. 2021; 99 (2): 112–24. https://doi.org/10.2471/BLT.20.267112.
7. Anser M.K., Sharif M., Khan M.A., et al. Demographic, psychological, and environmental factors affecting student's health during the COVID-19 pandemic: on the rocks. Environ Sci Pollut Res. 2021; 28: 31596–606. https://doi.org/10.1007/s11356-021-12991-x.
8. Eilersen A., Sneppen K. Cost-benefit of limited isolation and testing in COVID-19 mitigation. Sci Rep. 2020; 10 (1): 18543. https://doi.org/10.1038/s41598-020-75640-2.
9. Risko N., Werner K., Offorjebe O.A., et al. Cost-effectiveness and return on investment of protecting health workers in low- and middle income countries during the COVID-19 pandemic. PLoS One. 2020; 15 (10): e0240503. https://doi.org/10.1371/journal.pone.0240503.
10. Molochkov A.V., Karateev D.E., Ogneva E.Yu., et al. Comorbidities and predicting the outcome of COVID-19: the treatment results of 13,585 patients hospitalized in the Moscow Region. Almanac of Clinical Medicine. 2020; 48 (S1): 1–10 (in Russ.). https://doi.org/10.18786/2072-0505-2020-48-040.
11. Kouidere A., Youssoufi L.E., Ferjouchia H., et al. Optimal control of mathematical modeling of the spread of the COVID-19 pandemic with highlighting the negative impact of quarantine on diabetics people with cost-effectiveness. Chaos Solitons Fractals. 2021; 145: 110777. https://doi.org/10.1016/j.chaos.2021.110777.
12. Baggett T.P., Scott J.A., Le M.H., et al. Clinical outcomes, costs, and cost-effectiveness of strategies for adults experiencing sheltered homelessness during the COVID-19 pandemic. JAMA Netw Open. 2020; 3 (12): e2028195. https://doi.org/10.1001/jamanetworkopen.2020.28195.
13. Hota S., Fried E., Burry L., et al. Preparing your intensive care unit for the second wave of H1N1 and future surges. Crit Care Med. 2010; 38 (4 Suppl.): e110–9. https://doi.org/10.1097/CCM.0b013e3181c66940.
14. COVID19Surge: software to estimate the impact of COVID-19 pandemic on hospital surge capacity (Beta test version). Available at: https://www.cdc.gov/coronavirus/2019-ncov/downloads/covid19surge/COVID19Surge-Manual.pdf (accessed 28.05.2021).
15. Aziz S., Arabi Y.M., Alhazzani W., et al. Managing ICU surge during the COVID-19 crisis: rapid guidelines. Intensive Care Med. 2020; 46: 1303–25. https://doi.org/10.1007/s00134-020-06092-5.
16. Llorens P., Moreno-Pérez O., Espinosa B., et al. An integrated emergency department/hospital at home model in mild COVID-19 pneumonia: feasibility and outcomes after discharge from the emergency department. Intern Emerg Med. 2021; 16: 1673–82. https://doi.org/10.1007/s11739-021-02661-8.
17. Ding Q., Zhao H. Study on e-commerce logistics cost control methods in the context of COVID-19 prevention and control. Soft Comput. 2021; 25: 11955–63. https://doi.org/10.1007/s00500-021-05624-5.
18. Leonardi Vinci D., Meccio A., Provenzani A., et al. The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic. Eur J Hosp Pharm. 2021 Feb: ejhpharm-2020-002633. https://doi.org/10.1136/ejhpharm-2020-002633.
19. Cleary S.M., Wilkinson T., Tamandjou Tchuem C.R., et al. Cost effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa. BMC Health Serv Res. 2021; 21 (1): 82. https://doi.org/10.1186/s12913-021-06081-4.
20. Gandjour A. How many intensive care beds are justifiable for hospital pandemic preparedness? A cost-effectiveness analysis for COVID-19 in Germany. Appl Health Econ Health Policy. 2021; 19 (2): 181–90. https://doi.org/10.1007/s40258-020-00632-2.
21. Anand N., Sabarinath A., Geetha S., Somanath S. Predicting the spread of COVID19 using SIR model augmented to incorporate quarantine and testing. Trans Indian Natl Acad Eng. 2020; 5: 141–8. https://doi.org/10.1007/s41403-020-00151-5.
22. Du Z., Pandey A., Bai Y., et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health. 2021; 6 (3): e184–91. https://doi.org/10.1016/S2468-2667(21)00002-5.
23. Jo Y., Jamieson L., Edoka I., et al. Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa. Open Forum Infect Dis. 2021; 8 (3): ofab040. https://doi.org/10.1093/ofid/ofab040.
24. Kerboua K.E. NLR: a cost-effective nomogram to guide therapeutic interventions in COVID-19. Immunol Invest. 2021; 50 (1): 92–100. https://doi.org/10.1080/08820139.2020.1773850.
25. Balykova L.A., Govorov A.V., Vasilyev A.O., et al. Characteristics of covid-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice. Infectious Diseases. 2020; 18 (3): 30–40 (in Russ.). https://doi.org/10.20953/1729-9225-2020-3-30-40.
26. Mishinova S.A., Zhuravkov A.A., Zhuravko V.K. Use of unlicensed drugs and off-label drug use: focus on COVID-19. Kachestvennaya klinicheskaya praktika / Good Clinical Practice. 2020; S4: 120–9 (in Russ). https://doi.org/10.37489/2588-0519-2020-S4-120-129.
27. Shulakova O.A., Zyryanov S.K., Gurevich K.G. Off-label drug usage in the treatment of urinary tract infection of newborns. Eksperimental'naya i klinicheskaya farmakologiya / Experimental and Clinical Pharmacology. 2015; 78 (12): 36–40 (in Russ). https://doi.org/10.30906/0869-2092-2015-78-12-36-40.
28. Smoke S.M., Raja K., Hilden P., Daniel N.M. Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study. Int J Antimicrob Agents. 2021; 57 (2): 106265. https://doi.org/10.1016/j.ijantimicag.2020.106265.
29. Kulanthaivel S., Kaliberdenko V.B., Balasundaram K. Tocilizumab in Sars-CoV-2 patients with the syndrome of cytokine storm; a narrative review. Rev Recent Clin Trails. 2021; 16 (2): 138–45. https://doi.org/10.2174/1574887115666200917110954.
30. Nasonov E., Samsonov M. The role of interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020; 131: 110698. https://doi.org/10.1016/j.biopha.2020.110698.
31. Tang Y., Liu J., Zhang D., et al. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020; 11: 1708. https://doi.org/10.3389/fimmu.2020.01708.
32. Kaye A.G., Siegel R. The efficacy of IL-6 inhibitor tocilizumab in reducing severe COVID-19 mortality: a systematic review. Peer J. 2020; 8: e10322. https://doi.org/10.7717/peerj.10322.
33. Boregowda U., Perisetti A., Nanjappa A., Gajendran M. Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2020; 7: 586221. https://doi.org/10.3389/fmed.2020.586221.
34. Uslu S. Effectiveness of tocilizumab in a COVID-19 patient with cytokine release syndrome. Eur J Case Rep Intern Med. 2020; 7 (6): 001731. https://doi.org/10.12890/2020_001731.
35. Du P., Geng J., Wang F., et al. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci. 2021; 18 (6): 1356–62. https://doi.org/10.7150/ijms.53564.
36. De Stefano L., Bobbio-Pallavicini F., Manzo A., et al. A “Window of Therapeutic Opportunity” for anti-cytokine therapy in patients with coronavirus disease 2019. Front Immunol. 2020; 11: 572635. https://doi.org/10.3389/fimmu.2020.572635.
37. Deckert A., Anders S., de Allegri M., et al. Effectiveness and cost effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Trials. 2021; 22 (1): 39. https://doi.org/10.1186/s13063-020-04982-z.
38. Kouidere A., Kada D., Balatif O., et al. Optimal control approach of a mathematical modeling with multiple delays of the negative impact of delays in applying preventive precautions against the spread of the COVID-19 pandemic with a case study of Brazil and cost-effectiveness. Chaos Solitons Fractals. 2021; 142: 110438. https://doi.org/10.1016/j.chaos.2020.110438.
39. ICU bed reserve capacity for COVID-19 cost effective in Germany. PharmacoEcon Outcomes News. 2021; 870 (1): 10. https://doi.org/10.1007/s40274-021-7413-9.
40. Swain K.C., Singha C. Low-cost technology for COVID-19 infection detection through smell loss test: an overview. Trop Biomed. 2020; 37 (3): 671–82. https://doi.org/10.47665/tb.37.3.671.
41. Durner J., Burggraf S., Czibere L., et al. Fast and cost-effective screening for SARS-CoV-2 variants in a routine diagnostic setting. Dent Mater.2021; 37 (3): e95–7. https://doi.org/10.1016/j.dental.2021.01.015.
42. Agarwal R., Gupta E., Dubey S., et al. Pooled nasopharyngeal swab collection in a single vial for the diagnosis of SARS CoV-2 infection: an effective cost saving method. Indian J Med Microbiol. 2021; 39 (2): 231–4. https://doi.org/10.1016/j.ijmmb.2020.11.002.
43. Neilan A.M., Losina E., Bangs A.C., et al. Clinical impact, costs, and cost-effectiveness of expanded SARS-CoV-2 testing in Massachusetts. Clin Infect Dis. 2020: ciaa1418. https://doi.org/10.1093/cid/ciaa1418.
44. Bagepally B.S., Haridoss M., Natarajan M., et al. Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clin Epidemiol Glob Health. 2021; 10: 100702. https://doi.org/10.1016/j.cegh.2021.100702.
45. Chaturvedi S., Gupta A., Krishnan S.V., Bhat A.K. Design, usage and review of a cost effective and innovative face shield in a tertiary care teaching hospital during COVID-19 pandemic. J Orthop. 2020; 21: 331–6. https://doi.org/10.1016/j.jor.2020.07.003.
46. Asamoah J.K., Owusu M.A., Jin Z., et al. Global stability and cost effectiveness analysis of COVID-19 considering the impact of the environment: using data from Ghana. Chaos Solitons Fractals. 2020; 140: 110103. https://doi.org/10.1016/j.chaos.2020.110103.
47. Ebigbo A., Römmele C., Bartenschlager C., et al. Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre endoscopic virus testing and use of high risk personal protective equipment. Endoscopy. 2021; 53 (2): 156–61. https://doi.org/10.1055/a-1294-0427.
48. Yu Y., Lau J.T., Lau M.M. Understanding the prevalence and associated factors of behavioral intention of COVID-19 vaccination under specific scenarios combining effectiveness, safety, and cost in the Hong Kong Chinese general population. Int J Health Policy Manag. 2021 Jan 18. https://doi.org/10.34172/ijhpm.2021.02.
49. COVID-19 vaccination predicted to be cost effective in USA. PharmacoEcon Outcomes News. 2021; 871 (1): 10. https://doi.org/10.1007/s40274-021-7448-y.
50. Kohli M., Maschio M., Becker D., Weinstein M.C. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021; 39 (7): 1157–64. https://doi.org/10.1016/j.vaccine.2020.12.078.
51. Sookaromdee P., Wiwanitkit V. New COVID-19 vaccines, its cost and shelf life: a cost effectiveness analysis. Arch Med Res. 2021; 52 (4): 453. https://doi.org/10.1016/j.arcmed.2020.12.008.
52. Berry D.A., Berry S., Hale P., et al. A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. PLoS One. 2020; 15 (12): e0244418. https://doi.org/10.1371/journal.pone.0244418.
53. Gu T., Yao L., Meng X., et al. A cost-effective plan for global testing – an infection rate stratified, algorithm guided, multiple-level, continuously pooled testing strategy. Sci Total Environ. 2021; 765: 144251. https://doi.org/10.1016/j.scitotenv.2020.144251.
Review
For citations:
Rogova I.V., Zhidkova E.A., Popova I.A., Zaborovskiy A.V., Gurevich K.G. Pharmacoeconomic aspects of COVID-19 treatment. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(3):357-364. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.086
Views:
1694
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 